Chembridge-5861528 TCS 5861528|cas:332117-28-9|西域试剂

Chembridge-5861528 TCS 5861528,99.27%

产品编号：Bellancom-15065| CAS NO：332117-28-9| 分子式：C₁₉H₂₃N₅O₃| 分子量：369.42

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-15065	￥750.00	杭州北京（现货）
Bellancom-15065	￥1200.00	杭州北京（现货）
Bellancom-15065	￥5000.00	杭州北京（现货）
Bellancom-15065	￥8000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Chembridge-5861528 TCS 5861528

产品介绍

Chembridge-5861528 (TCS 5861528) 是一种有效的 TRPA1 通道拮抗剂，可拮抗异硫氰酸烯丙基和 4-HNE 诱发的 TRPA1 反应，IC₅₀ 值分别为 14.3 μM 和 18.7 μM。Chembridge-5861528 具有抗过敏效果。

生物活性

Chembridge-5861528 (TCS 5861528) is a potent TRPA1 channel antagonist that antagonizes similarly allyl isothiocyanate- and 4-HNE-evoked TRPA1 responses, with IC₅₀ values of 14.3 μM and 18.7 μM, respectively. Chembridge-5861528 shows antihypersensitivity activities.

体外研究

Chembridge-5861528 (TCS 5861528) shows no TRPA1 or TRPV1 channel agonism and no TRPV1 channel antagonism up to a dose of 100 μM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Chembridge-5861528 (TCS 5861528) (30 mg/kg; i.p.; twice daily for a week) significantly attenuates development of mechanical hypersensitivity in Streptozocin (HY-13753)-induced diabetes mellitus rat model.
Chembridge-5861528 (3 and 10 μg/rat; i.t.; once) attenuates Capsaicin (HY-10448)-induced blood flow increase in a dose-related fashion.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Hannover-Wistar rats, Streptozocin-induced diabetes mellitus model
Dosage:	30 mg/kg
Administration:	Intraperitoneal injection, twice daily for a week
Result:	Significantly attenuated development of mechanical hypersensitivity as revealed by the paw pressure test (F^1,80= 31.4, P < 0.0001).

Animal Model:	Male Hannover–Wistar rats (220-260 g), Capsaicin-induced neurogenic inflammation model
Dosage:	0, 3, and 10 μg/rat
Administration:	Intrathecal injection, 20 min before Capsaicin injection
Result:	Significantly decreased the blood flow at 10 μg.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Hannover-Wistar rats, Streptozocin-induced diabetes mellitus model
Dosage:	30 mg/kg
Administration:	Intraperitoneal injection, twice daily for a week
Result:	Significantly attenuated development of mechanical hypersensitivity as revealed by the paw pressure test (F^1,80= 31.4, P < 0.0001).

Animal Model:	Male Hannover–Wistar rats (220-260 g), Capsaicin-induced neurogenic inflammation model
Dosage:	0, 3, and 10 μg/rat
Administration:	Intrathecal injection, 20 min before Capsaicin injection
Result:	Significantly decreased the blood flow at 10 μg.

性状

Solid

溶解性数据

In Vitro:

DMSO : 120 mg/mL (324.83 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7069 mL	13.5347 mL	27.0695 mL
5 mM	0.5414 mL	2.7069 mL	5.4139 mL
10 mM	0.2707 mL	1.3535 mL	2.7069 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 3 mg/mL (8.12 mM); Clear solution

此方案可获得 ≥ 3 mg/mL (8.12 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 30.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 3 mg/mL (8.12 mM); Clear solution

此方案可获得 ≥ 3 mg/mL (8.12 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 30.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。